Claims for Patent: 8,466,340

Summary for Patent: 8,466,340

Title:	Mouse model for pompe disease and methods of use thereof
Abstract:	The present invention provides mouse models for Pompe disease and methods of using the same to test agents that may be effective in the treatment of Pompe disease.
Inventor(s):	Khanna; Richie (Piscataway, NJ), Toth; Matthew J. (Iselin, NJ)
Assignee:	Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:	13/202,045
Patent Claims:	1. A mouse model for Pompe disease comprising a knockout transgenic mouse wherein the endogenous alpha-glucosidase gene is disrupted such that the knockout transgenic mouse lacks the capacity to express the gene for mouse alpha-glucosidase and whose genome comprises at least a P545L mutation in a gene encoding human alpha-glucosidase, wherein the amount of human alpha-glucosidase protein expressed and the level of human alpha-glucosidase activity in at least one disease-relevant tissue of the knockout transgenic mouse is in a range of about 3% to about 10% relative to that of a wild-type mouse, where the at least one disease-relevant tissue is selected from the group consisting of: heart, diaphragm, skeletal muscle, skin, and brain. 2. A mouse model for Pompe disease comprising a knockout transgenic mouse wherein the endogenous alpha-glucosidase gene is disrupted such that the knockout transgenic mouse lacks the capacity to express the gene for mouse alpha-glucosidase and whose genome comprises at least a P545L mutation in a gene encoding human alpha-glucosidase, wherein the level of glycogen in at least one disease-relevant tissue of the knockout transgenic mouse is at least 2-fold higher than a wild-type mouse, where the at least one disease-relevant tissue is selected from the group consisting of: heart, diaphragm, skeletal muscle, skin, and brain. 3. A method of screening for a therapeutic agent for Pompe disease, comprising administering a test agent to the knockout transgenic mouse of claim 1 and evaluating the effect of the test agent on at least one of: the amount of alpha-glucosidase protein, the level of alpha-glucosidase activity or the level of glycogen in at least one disease-relevant tissue of the knockout transgenic mouse, wherein at least one of: an increase in the amount of alpha-glucosidase protein, an increase in the level of alpha-glucosidase activity or a reduction in the level of glycogen in at least one disease-relevant tissue relative to a similar knockout transgenic mouse that does not receive the test agent indicates the test agent is therapeutic for Pompe disease. 4. A method for assessing one or more agents for the treatment of Pompe disease, comprising administering one or more agents to the knockout transgenic mouse of claim 1 and evaluating the effect of the agents on at least one of: the amount of alpha-glucosidase protein, the level of alpha-glucosidase activity or the level of glycogen in at least one disease-relevant tissue of the knockout transgenic mouse, wherein at least one of: an increase in the amount of alpha-glucosidase protein, an increase in the level of alpha-glucosidase activity or a reduction in the level of glycogen in at least one disease-relevant tissue as compared to a similar knockout transgenic mouse that does not receive one or more agents is therapeutic for Pompe disease. 5. The method of claim 4 wherein one or more agents is a pharmacological chaperone, a recombinant alpha glucosidase, an antineoplastic agent, an antirheumatic agent, a reproductive control agent, or any combination of two or more thereof. 6. The method of claim 4 wherein one or more agents is DNJ, recombinant alpha glucosidase, Cyclophosphamide, Methotrexate, Rituximab, or any combination of two or more thereof. 7. The method of claim 6 wherein one or more agents includes DNJ and recombinant alpha glucosidase. 8. The method of claim 6 wherein one or more agents includes DNJ. 9. The knockout transgenic mouse of claim 1 wherein the level of glycogen in at least one disease-relevant tissue of the knockout transgenic mouse is at least 2-fold higher than that of a wild-type mouse. 10. A method of screening for a therapeutic agent for Pompe disease, comprising administering a test agent to the knockout transgenic mouse of claim 2 and evaluating the effect of the test agent on at least one of: the amount of alpha-glucosidase protein, the level of alpha-glucosidase activity or the level of glycogen in at least one disease-relevant tissue of the knockout transgenic mouse, wherein at least one of: an increase in the amount of alpha-glucosidase protein, an increase in the level of alpha-glucosidase activity or a reduction in the level of glycogen in at least one disease relevant tissue relative to a similar knockout transgenic mouse that does not receive the test agent indicates the test agent is therapeutic for Pompe disease. 11. A method for assessing one or more agents for the treatment of Pompe disease, comprising administering one or more agents to the knockout transgenic mouse of claim 2 and evaluating the effect of the agents on at least one of: the amount of alpha-glucosidase protein, the level of alpha-glucosidase activity or the level of glycogen in at least one disease-relevant tissue of the knockout transgenic mouse, wherein at least one of: an increase in the amount of alphaglucosidase protein, an increase in the level of alpha-glucosidase activity or a reduction in the level of glycogen in at least one disease-relevant tissue as compared to a similar knockout transgenic mouse that does not receive one or more agents is therapeutic for Pompe disease.

Details for Patent 8,466,340

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2029-02-18
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2029-02-18
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2029-02-18